UltraShort Nasdaq Biotechnology
ProShares UltraShort Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the inverse (opposite) of the daily performance of the NASDAQ Biotechnology® Index.
Product Menu:
Index/Benchmark Summary
The NASDAQ Biotechnology Index is a modified capitalization weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The securities also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc., including minimum market capitalization and liquidity requirements.
As of 12/31/11
Fundamentals
| Total Number of Companies |
Price/Earnings Ratio |
Price/Book Ratio |
Dividend Yield 1 (%) |
Average Index Market Capitalization |
|---|---|---|---|---|
| 119 | 108.59 | 4.42 | 0.22 | $3.01 billion |
1 = Derivative contracts are priced to reflect the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives, they will not have dividend distributions that reflect those of their applicable indexes.
| Top 10 Index Companies 2 | Weight |
|---|---|
| Pharmasset Inc. | 11.20% |
| Amgen Inc. | 7.86% |
| Alexion Pharmaceuticals Inc. | 6.14% |
| Celgene Corp. | 5.82% |
| Gilead Sciences Inc. | 4.74% |
| Biogen Idec Inc. | 4.58% |
| Teva Pharmaceutical ¿ SP ADR | 4.34% |
| Perrigo Co. | 3.95% |
| Regeneron Pharmaceuticals | 3.28% |
| Vertex Pharmaceuticals Inc. | 2.94% |
2 = ProShares may invest in financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark.
| Index Sector Weightings 3 | Weight |
|---|---|
| Biotechnology | 52.52% |
| Pharmaceuticals | 43.75% |
| Healthcare-Products | 3.41% |
| Commercial Services | 0.32% |
3 = Sum of weightings may not equal 100% due to rounding.